JCR Pharmaceuticals

pivot change turnaround direction walk away

Takeda’s gene therapy pivot leaves JCR behind

JCR has achieved proof of concept for its gene therapy technology—just in time to lose partner Takeda as the pharma pivots away from AAV gene therapy.

Annalee Armstrong Dec 21, 2023 8:57am

Angelini, JCR pen epilepsy deal worth up to $505M biobucks

May 11, 2023 11:00am